Can a meningitis vaccine be safe in pregnancy? a registry aims to find out
NCT ID NCT07768163
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This registry study follows pregnant individuals aged 10 to 25 who received PENBRAYA, a vaccine against meningococcal disease, during pregnancy or within 30 days before their last period. The goal is to collect information on pregnancy outcomes and infant health during the first year of life, including birth defects, preterm birth, and growth. No extra tests or visits are needed—data is gathered remotely from participants and their doctors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PENBRAYA (meningococcal vaccine)
- What this could lead to
- If this registry finds no safety concerns, it could support the use of PENBRAYA in pregnant individuals, protecting them and their babies from meningococcal disease.
- What could go wrong
- This is a small observational registry, not a controlled trial, so it may not detect rare or long-term effects. The vaccine's safety in pregnancy is still not fully established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGOCOCCAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer New York
RECRUITINGNew York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.